Author name: Claritas Rx

In the intricate web of healthcare, where policy, economics, and patient care converge, rises a contentious practice known as step therapy. Often lauded by insurers for its cost-controlling prowess, step therapy sows seeds of uncertainty for many patients, forcing them to navigate a labyrinth of medications before laying claim to the treatment their doctors initially […]

The world of specialty pharmaceuticals consistently brings forth groundbreaking therapies, bringing hope to patients suffering from previously incurable conditions. However, their success heavily depends on patient adherence. An in-depth examination of patient journeys indicates a concerning fact – a sizeable number of patients, prescribed these potentially life-saving specialty drugs, discontinue their treatment plans frequently before their

Navigating the patient treatment journey is like solving a complex puzzle for the pharmaceutical industry. At every turn, there are challenges, most notably the phenomenon of patient treatment abandonment. Imagine spending years developing a drug that could potentially save thousands of lives, only to find out that a significant portion of patients who should be

Specialty pharmacists can help patients changing payers or providers, and specialty pharmacy data helps with medication adherence strategies.

Specialty pharmacy distribution is changing as specialty drug treatments become more commonplace. Many biosimilars have entered the rare disease market, directly competing with biologics like Humira that represented breakthroughs in their time. New treatments for a wide range of conditions are also available, including biologics, cell and gene therapies for rare diseases.  Wider adoption of

Patients readily switch doctors, making medication adherence strategies difficult. Specialty pharmacy data can assist with the patient journey orchestration.

Specialty pharmacists can help patients changing payers or providers, and specialty pharmacy data helps with medication adherence strategies.

A look at pharma market insights plus regulatory news updates from the FDA and related agencies to wrap up 2023.